The design and potential for success of the Phase II trial is only as good as the quality of the preclinical
assays. Those assays guide them to asking the right questions. I prefer any delay in getting the PPL1 report
out as opposed to rushing it through to satisfy the emotions of shareholders.
IMO
Ann: Epichem's New Laboratory Completed, page-96
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $92.38M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 18.5¢ | $382.4K | 2.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 178766 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 361999 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |